The Database Nobody Can Buy

Revenue up 79%. Stock down 57%. The market is confused. We are not.

A company that burned through $245 million in a single year just flipped to positive free cash flow. Revenue grew 79% in the most recent quarter. The stock is down 57% from its all-time high. It just launched three new products powered by the same database that took eighteen years to build. And the most sophisticated institutional investors in precision oncology are accumulating.

This is the kind of setup that has made fortunes in healthcare.

The company sits at the intersection of molecular biology, artificial intelligence, and early cancer detection — three of the most consequential forces in medicine over the next two decades. It owns a database that cannot be replicated. Its pricing power is rising every quarter. Its cash flow has inflected. And the market has not yet decided what to do with it.

The window to enter before consensus forms is open. It will not stay open long.

Join FJR now to read the full analysis — including the company name, the ticker, the full business breakdown, the competitive landscape, the risk assessment, and where I stand on valuation.

$49 a year. Yes a year!